Capricor Therapeutics (CAPR) Net Margin (2011 - 2024)
Capricor Therapeutics' (CAPR) quarterly Net Margin came in at 65.01% in Q4 2024, down 5373.0% year-on-year from 1.23% in Q1 2024, and up 98.88% quarter-over-quarter from 5794.83% in Q3 2024.
Capricor Therapeutics (CAPR) Net Margin (2011 - 2024) Analysis & Trends
Capricor Therapeutics' Net Margin history runs 13 years deep, the most recent figure standing at 65.01% for Q4 2024.
- On a quarterly basis, Net Margin fell 5373.0% year-over-year to 65.01% in Q4 2024; TTM through Sep 2025 was 1622.12%, a 92726.0% decrease from a year earlier, with the FY2024 full-year figure at 181.71%, down 3697.0% from the prior year.
- Net Margin climbed to 65.01% in Q4 2024 per CAPR's latest filing, from 5794.83% in the prior quarter.
- Across five years, Net Margin topped out at 11.28% in Q4 2023 and bottomed at 71092.46% in Q3 2020.
- The 5-year median for Net Margin is 968.75% (2020), against an average of 7873.7%.
- Across the five-year window, Net Margin tumbled 6988160 bps in 2020 and surged 1879918 bps in 2021, its largest moves.
- Year by year, Net Margin stood at 7229.02% in 2020, then soared by 66 bps to 2482.54% in 2021, then jumped by 69 bps to 768.91% in 2022, then jumped by 99 bps to 11.28% in 2023, then slumped by 476 bps to 65.01% in 2024.
- Per Business Quant, the three latest CAPR Net Margin figures stand at 65.01% (Q4 2024), 5794.83% (Q3 2024), and 582.84% (Q2 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Capricor Therapeutics | 457.86 Mn | 457.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -65.01% |
| Sep 30, 2024 | -5,794.83% |
| Jun 30, 2024 | -582.84% |
| Mar 31, 2024 | -412.24% |
| Dec 31, 2023 | -11.28% |
| Sep 30, 2023 | -171.74% |
| Jun 30, 2023 | -497.20% |
| Mar 31, 2023 | -275.46% |
| Dec 31, 2022 | -768.91% |
| Sep 30, 2022 | -1,523.03% |
| Jun 30, 2021 | -2,482.54% |
| Mar 31, 2021 | -12,622.31% |
| Dec 31, 2020 | -7,229.02% |
| Sep 30, 2020 | -71,092.46% |
| Jun 30, 2020 | -21,281.72% |
| Mar 31, 2020 | -1,168.58% |
| Dec 31, 2019 | -661.60% |
| Sep 30, 2019 | -1,210.86% |
| Jun 30, 2019 | -503.64% |
| Mar 31, 2019 | -1,308.05% |